Key result
Non vitamin-K oral anticoagulants offer easier handling and a more favorable risk-benefit profile compared to warfarin for cardioembolic stroke prevention.
Why the study?
Do NOACs provide a more favorable risk-benefit profile compared to warfarin for cardioembolic stroke prevention?
Do NOACs provide a more favorable risk-benefit profile compared to warfarin for cardioembolic stroke prevention?
NOACs are increasingly preferred over warfarin for stroke prevention due to easier handling, a favorable risk-benefit profile, and the availability of specific reversal agents.
Answers are grounded in this paper and cite their sources.
May support NOAC preference in cardioembolic prevention; leaves open guideline updates pending higher-level evidence.
INTRODUCTION: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events. Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases. Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists. New evidences have suggested their use in treatment of elderly people, in patients with renal insufficiency or with antiphospholipid antibody syndrome. In addition, the use of antidotes, which rapidly reverse the anticoagulant effect of the NOACs, could be useful in bleeding, during emergency procedures, or in case of overdose.
No takes yet. Share an insight, caveat, or question.
Arnao et al. (2016) conducted a review in Cardioembolic stroke prevention. Non vitamin-K oral anticoagulants (NOACs) vs. Warfarin was evaluated. Non vitamin-K oral anticoagulants offer easier handling and a more favorable risk-benefit profile compared to warfarin for cardioembolic stroke prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: